Roche YTD September 2017 salesbf6a0b14-e682-4af8-b4e1-7cc59c2e23… · 3 This presentation contains certain forward-looking statements. These forward-looking statements may be identified

Roche

YTD September 2017 sales

Basel, 19 October 2017

3

This presentation contains certain forward-looking statements. These forward-looking

statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’,

‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among

other things, strategy, goals, plans or intentions. Various factors may cause actual results to

differ materially in the future from those reflected in forward-looking statements contained in

this presentation, among others:

1 pricing and product initiatives of competitors;

2 legislative and regulatory developments and economic conditions;

3 delay or inability in obtaining regulatory approvals or bringing products to market;

4 fluctuations in currency exchange rates and general financial market conditions;

5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;

6 increased government pricing pressures;

7 interruptions in production;

8 loss of or inability to obtain adequate protection for intellectual property rights;

9 litigation;

10 loss of key executives or other employees; and

11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to

mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily

match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website

www.roche.com

All mentioned trademarks are legally protected.

4

Group Severin Schwan Chief Executive Officer

YTD Sept 2017 performance

Outlook

5

YTD Sept 2017: Strong sales growth in both

divisions

6 CER=Constant Exchange Rates

2017 2016

CHFbn CHFbn CHF CER

Pharmaceuticals Division 30.6 29.1 5 5

Diagnostics Division 8.8 8.4 5 5

Roche Group 39.4 37.5 5 5

Change in %

YTD Sept 2017: Strong sales growth in US and

International

7

0

2

4

6

8

10

12

14

16

18

Japan International Europe US

Diagnostics

Pharma

CHFbn

+10%

-2% +4%

+2%

+1% +14%

+1%

-1%

+8%

-1%

+2%

+7%

All growth rates at Constant Exchange Rates (CER)

Q3 2017: Sales growth for the sixth consecutive

year

8

2%

6%

4%

6% 6%

4%

8%

7%

5%

4%

5%

6%

5%

7%

6%

4% 4%

6%

3% 3%

4%

6% 6%

0%

2%

4%

6%

8%

10%

Q1

12

Q2

12

Q3

12

Q4

12

Q1

13

Q2

13

Q3

13

Q4

13

Q1

14

Q2

14

Q3

14

Q4

14

Q1

15

Q2

15

Q3

15

Q4

15

Q1

16

Q2

16

Q3

16

Q4

16

Q1

17

Q2

17

Q3

17


YTD Sep 2017: Successful launch activities

Differentiation driving growth

9

• EU: Positive CHMP opinion in 1L ALK+ NSCLC

• US: 1L under FDA priority review and listing in NCCN

guidelines as category 1 preferred option

• EU approval in bladder (1/2L) & lung (2L)

• Approved in RMS & PPMS: US, CH, Australia

• Positive early feedback from all stakeholders

Additional sales

of recent launches

+900m

Ocrevus

+500m

Alecensa

+122m

Tecentriq

+278m

CHF

PPMS=primary progressive multiple sclerosis; RMS=relapsing forms of multiple sclerosis; NCCN=National Comprehensive Cancer Network;

CHMP=Committee for Medicinal Products for Human Use

Total:

Q3 2017: Sustainable Roche business case

Important milestones achieved

10

HER2 franchise Perjeta in adjuvant BC (APHINITY) US priority review, EU filed

CD20/Hematology

Gazyva in 1L iNHL (GALLIUM)

Venclexta in R/R CLL (MURANO)

Polatuzumab in R/R DLBCL (Ph II)

US priority review, EU approved

Ph 3 met primary endpoint

BTD, EU PRIME designation

Cancer Immunotherapy Tecentriq EU approved in bladder and lung

Lung cancer Alecensa in 1L ALK+ NSCLC US priority review, positive CHMP opinion

Hemophilia A Emicizumab in inhibitors

(HAVEN 1 and 2)

BTD, US priority review, EU accelerated

assessment

Neuroscience Ocrevus Additional approvals in AUS, CAN, CH

Spinal Muscular Atrophy SMN2 splicer (SUNFISH) Ph 1b at WMS* – Pivotal Ph III initiated

* WMS=World Muscle Society, October 2017; BTD=breakthrough therapy designation

Roche significantly advancing patient care

Recognition for innovation 2013-present

11

Rank Company #

1 Roche 18

2 Novartis 15

3 BMS 10

4 Merck 9

4 Pfizer 9

18 Breakthrough Therapy Designations

Source: http://www.focr.org/breakthrough-therapies as of October 2017; BR=bendamustin+Rituxan; DLBCL=diffuse large B cell lymphoma; LDAC=low dose cytarabine;

AML=acute myeloid leukemia; ECD=Erdheim-Chester disease; NSCLC=non-small cell lung cancer; PPMS=primary progressive multiple sclerosis; HMA=hypomethylating

agent; CLL=chronic lymphocytic leukemia; IPF=idiopathic pulmonary fibrosis

http://www.focr.org/breakthrough-therapies



YTD Sept 2017 performance

Outlook

12

Aiming to set new standards of care

Upcoming readouts for CIT & Hematology

13

Readouts:

(Q4 17 to Q2 18)

Most comprehensive lung cancer program

addressing all common backbones Lung

5 trials in non-squamous,

squamous & small cell

lung cancer

Among the leaders in renal cancer GU 1L RCC

First-in-class in colorectal cancer CRC 2/3L CRC

First-in-class in triple negative breast cancer Breast 1L TNBC

First-in-class in non-inhibitor hemophilia A Hemophilia Non-inhibitors and

monthly schedule

Launch of new medicines at a record high

2011 2012 2013 2014 2015 2016 2017

Emicizumab

(filed)

14

2017 outlook raised at HY

15

Group sales growth1 Mid-single digit

Core EPS growth1 Broadly in line with sales growth

Dividend outlook Further increase dividend in Swiss francs

1 At Constant Exchange Rates (CER)

16

Pharmaceuticals Division Daniel O’Day CEO Roche Pharmaceuticals

YTD Sept 2017 sales

Innovation

Outlook

17

YTD Sept 2017: Pharma sales

Strong growth in US due to ongoing launches


2017 2016

CHFm CHFm CHF CER

Pharmaceuticals Division 30,636 29,140 5 5

United States 15,266 13,850 10 10

Europe 6,766 6,916 -2 -2

Japan 2,675 2,690 -1 2

International 5,929 5,684 4 4

Change in %

YTD Sept 2017: Strong sales performance with

increasing contribution from new launches

19 Absolute values and growth rates at Constant Exchange Rates (CER)

-250 -150 -50 50 150 250 350 450 550

Tarceva

Avastin

Tamiflu

Pegasys

Lucentis

Esbriet

Activase/TNKase

Herceptin

Alecensa

MabThera/Rituxan

Actemra/RoActemra

Xolair

Perjeta

Tecentriq

Ocrevus

US

Europe

Japan

International-17%

+357%

+17%

+17%

+13%

+102%

+2%

-2%

-21%

+14%

CHFm

-36%

+11%

+2%

n/a

+4%

0 5 10

Cotellic +

Zelboraf

Alecensa

Tecentriq

Tarceva

CD20

Avastin

HER2

Perjeta

Herceptin

Kadcyla

+6%

-2%

-17%

+357%

+3%

Gazyva/Gazyvaro

Cotellic

MabThera/Rituxan

(Oncology)

-12%

+102%

20

YTD Sept 2017: Oncology with +3% growth

CHFbn

YoY CER growth

YTD Sept 2017 Oncology sales: CHF 19.2bn; All growth rates at Constant Exchange Rates (CER); CIT=cancer immunotherapy;

FL=follicular lymphoma; NCCN=National Comprehensive Cancer Network

• Increased competition

• Breast cancer reimbursement in France,

• CIT competition in US

• Perjeta: Strong growth in all regions

• Kadcyla: Growth driven by International, US, and EU

• US: Cotellic+Zelboraf stable 1/2L market share

• EU: Cotellic+Zelboraf increasing; Zelboraf mono declining

• US: NCCN category 1 listing in 1L as preferred option

• US/EU: 1L filing completed (Positive CHMP opinion)

• EU: Approval in lung (2/3L) and bladder (2L and 1L

cisplatin ineligible) achieved

• US: Gazyva in 1L FL (GALLIUM) on NCCN guidelines

• EU: Approval in 1L FL achieved

HER2 franchise: Growth driven by Perjeta and

Kadcyla

0

500

1,000

1,500

2,000

2,500

Q3 14 Q3 15 Q3 16 Q3 17

Herceptin Perjeta Kadcyla

+23%

YoY CER growth

+8%

+16%

CER=Constant Exchange Rates; BC=breast cancer; SC=subcutaneous

CHFm +5%

HER2 franchise Q3 2017

• Perjeta (+17%): Strong demand in

neoadj. and 1L BC driven by all regions

• Kadcyla (+10%): Growth in International,

US and EU

Outlook 2017

• US: Priority review for APHINITY (adj.

BC) with PDUFA date set for Jan 28

• EU filing of APHINITY completed

21

Immunology: Differentiation and new indications

contributing to strong growth

22

0

400

800

1,200

1,600

2,000

Q3 14 Q3 15 Q3 16 Q3 17

MabThera/Rituxan (RA) Actemra IVActemra SC XolairCellCept PulmozymeEsbriet Other

CHFm

CER=Constant Exchange Rates; CRS=cytokine release syndrom; GPA=granulomatosis with polyangiitis; MPA=microscopic polyangiitis

YoY CER growth

+15%

+23% +10%

+8% Immunology Q3 2017

Xolair (+17%)

• Asthma: US pediatrics launch ongoing;

only biologic approved for children

Actemra (+13%)

• EU approval in giant cell arteritis

• US approval for CRS

MabThera/Rituxan (+6%)

• Continues to grow in rheumatoid

arthritis and vasculitis (GPA and MPA)

23 DR=diabetic retinopathy; mCNV=myopic choroidal neovascularisation; wAMD=wet age-related macular degeneration; DME=diabetic

macular edema; MoA=mechanism of action

Lucentis Q3 2017

• US (+8%): Growth driven by prefilled

syringe and new indications DR and

mCNV

Outlook 2017/18

• Overall FY growth expected

• Ph II enrolment into port delivery study

completed; results expected in 2018

• Ph II results for anti-VEGF/Ang2 bispecific

antibody with dual MoA expected in 2018

Ophthalmology: Lucentis stabilized due to

prefilled syringe and new indications

Neuroscience: Ocrevus with excellent launch in

all treatment lines in RMS and PPMS

24 RMS=relapsing forms of multiple sclerosis; PPMS=primary progressive multiple sclerosis

0

100

200

300

400

Q1 17 Q2 17 Q3 17

US Europe International

CHFm Ocrevus Q3 2017

• Continued strong uptake in RMS and

PPMS (60/40) with some bolus in PPMS

• Market research indicates inroads in all

treatment lines in RMS

• RMS: 30% treatment naive/previously

discontinued vs. 70% switches from all

other approved medications

• Broad base of prescribers and high level

of US insurance coverage

Outlook 2017

• EU launch preparations on track

YTD Sept 2017 sales

Innovation

Outlook

25

Recognition for innovation 2013-present

Two additional BTDs in hematology received

26

Rank Company #

1 Roche 18

2 Novartis 15

3 BMS 10

4 Merck 9

4 Pfizer 9

18 Breakthrough Therapy Designations

Source: http://www.focr.org/breakthrough-therapies as of October 2017; BR=bendamustin+Rituxan; DLBCL=diffuse large B cell lymphoma; LDAC=low dose cytarabine;

AML=acute myeloid leukemia; ECD=Erdheim-Chester disease; NSCLC=non-small cell lung cancer; PPMS=primary progressive multiple sclerosis; HMA=hypomethylating

agent; CLL=chronic lymphocytic leukemia; IPF=idiopathic pulmonary fibrosis

= BTDs in blood cancer




Late-stage hematology: Improving the standard

of care and extending into new indications

27 ¹ Datamonitor; incidence rates includes the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK); CLL=chronic lymphoid leukemia; DLBCL (aNHL)=diffuse

large B-cell lymphoma; iNHL=indolent non-hodgkin`s lymphoma; AML=acute myeloid leukemia; MM=multiple myeloma; MDS=myelodysplastic syndrome; ALL=acute

lymphoblastic leukemia; Venclexta in collaboration with AbbVie; Gazyva in collaboration with Biogen; Polatuzumab vedotin in collaboration with Seattle Genetics

Incidence rates (330,000 pts1)

Ph III 1L (CLL14)

Ph III R/R (MURANO)

Ph III

Ph III

Polatuzumab

vedotin

+

Ph II R/R

Ph III 1L (POLARIX) +

Ph III Idasanutlin

28

Hematology pipeline progress in 2017

12 molecules in combination testing

* Venclexta in collaboration with AbbVie; Polatuzumab vedotin in collaboration with Seattle Genetics; Cotellic in collaboration with Exelixis; ChK1i in collaboration with

Array BioPharma; NHL=non-hodgkin`s lymphoma; CLL=chronic lymphoid leukemia; MM=multiple myeloma; MDS=myelodysplastic syndrom; AML=acute myeloid

leukemia

= progress in 2017

2x

2x

29

APHINITY: Perjeta+Herceptin in HER2+ eBC

Priority review by the FDA

von Minckwitz et al, ASCO 2017; eBC=early breast cancer (adjuvant setting); HR=hormone receptor; * Target population for Herceptin in adjuvant breast cancer

(US & EU5); current Herceptin penetration ~95%; Source: Datamonitor and internal estimates

• Risk of recurrence or death reduced by 19% in all patients, 23% in node+ and 24% in HR- patients

62 patients

113 patients

221 patients

Emicizumab’s clinical development plan

HAVEN 3 results expected in Q4

inhibitor adults/adolescents (≥12 years old), qw

2015 2016 2017 2018

Q1 Q2 Q3 Q4

inhibitor children (0–11 years old), qw

non-inhibitor/inhibitor adults/adolescents, q4w

non-inhibitor adults/adolescents (≥12 years old), qw and q2w

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

HAVEN1

Non-

interventional

HAVEN2

HAVEN3

HAVEN4

152 patients

48 patients

Q4

H1 2018

30

YTD Sept 2017 sales

Innovation

Outlook

31

Aiming to set new standards of care

Upcoming readouts for CIT & Hematology

32

Readouts:

(Q4 17 to Q2 18)

Most comprehensive lung cancer program

addressing all common backbones Lung

5 trials in non-squamous,

squamous & small cell

lung cancer

Among the leaders in renal cancer GU 1L RCC

First-in-class in colorectal cancer CRC 2/3L CRC

First-in-class in triple negative breast cancer Breast 1L TNBC

First-in-class in non-inhibitor hemophilia A Hemophilia Non-inhibitors and

monthly schedule

2017: Key late-stage news flow

Compound Indication Milestone

Regulatory

Alecensa 2L ALK+ NSCLC EU approval

Ocrevus RMS / PPMS US/EU launch

Tecentriq 1L cisplatin ineligible mUBC US approval

Tecentriq 2/3L NSCLC and 1/2L mUBC EU approval

Gazyva 1L FL (iNHL) US/EU filing

Actemra Giant cell arteritis US/EU approval

emicizumab Hemophilia A inhibitors US/EU filing

Phase III

readouts*

Perjeta + Herceptin Adjuvant HER2+ BC Ph III APHINITY

Alecensa 1L ALK+ NSCLC Ph III ALEX

Venclexta + Rituxan R/R CLL Ph III MURANO

Tecentriq + chemo/

Tecentriq + chemo + Avastin 1L NSCLC Ph III IMpower150

lampalizumab Geographic atrophy Ph III SPECTRI/CHROMA

emicizumab Hemophilia A non-inhibitors Ph III HAVEN3

33 Outcome studies are event-driven: timelines may change; mCNV=choroidal neovascularisation secondary to myopia

Additional YTD news flow:

• Lucentis: Approval in mCNV and diabetic retinopathy

• Rituxan Hycela for blood cancers approved and launched in the US

• Emicizumab: Positive interim results in pediatric inhibitors (HAVEN2)

• Gazyva 1L FL: EU approval achieved; FDA priority review (PDUFA date Dec 23)

• Alecensa 1L ALK+ NSCLC: Positive CHMP opinion and FDA priority review (PDUFA date Nov 30)

34

Diagnostics Division Roland Diggelmann CEO Roche Diagnostics

YTD Sept 2017: Diagnostics Division sales

Growth driven by CPS & Tissue Diagnostics


Underlying growth of Molecular Diagnostics excluding sequencing business: +4%

2017 2016

CHFm CHFm CHF CER

Diagnostics Division 8,798 8,365 5 5

Centralised and Point of Care Solutions 5,211 4,884 7 7

Diabetes Care 1,464 1,484 -1 -2

Molecular Diagnostics 1,388 1,345 3 3

Tissue Diagnostics 735 652 13 13

Change in %

North America

+1%

25% of divisional sales

Latin America

+11%


Japan

+1%

4% of divisional sales EMEA1

+3%


YTD Sept 2017: Diagnostics regional sales

Growth in all regions

Asia Pacific

+15%


36

+18% growth in E7 countries2

1 Europe, Middle East and Africa; 2 Brazil, China, India, Mexico, Russia, South Korea, Turkey All growth rates at Constant Exchange Rates

YTD Sept 2017: Diagnostics Division highlights

Growth driven by Immunodiagnostics

37

0.0 2.0 4.0 6.0

Tissue

Diagnostics

Molecular

Diagnostics

Diabetes

Care

Centralised

and Point of

Care

Solutions

EMEA

North America

RoW

+13%

-2%

+7%

+3%

CHFbn

1

1 Underlying growth of Molecular Diagnostics excluding sequencing business: +4%

CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa

YoY CER growth

• Driven by immunodiagnostics (+13%);

clinical chemistry (+3%)

• Continued US pricing and reimbursement

pressures

• Virology (-2%); Blood screening (+4%)

• Advanced staining portfolio (+10%); primary

staining (+13%) and companion diagnostics

(+32%)

Implementing the fully integrated core laboratory

38

Connecting disciplines

(cobas 6800/8800, cobas

6500, cobas p 612)

Seamless workflow and

laboratory IT

(cobas connection modules)

Highest throughput analysers

(cobas e 801, cobas c 702)

Comprehensive menu

(Procalcitonin; Zika; MPX;

Syphilis)

Digitalised data

management

(Navify tumor board)

Continued momentum of cobas e 801 placements

Completion of serology blood screening panel

39 Note: Serology assays are CE marked according to Directive 98/79/EC. Test performance has been established according to the Common Technical Specifications

(CTS) for diagnostic use and for screening of blood donations

*only on cobas e 801, HIV combi PT is continued on cobas e 602, e 601 and e 411

cobas e 801

• Double throughput on same footprint

• 517 instruments placed in 28 markets

Blood screening assays

HIV Duo*

Anti-HCV II

HBsAg II

Anti-HBc II

Anti-HBs II

HTLV-I/II

Syphilis

CMV lgG

CMV IgM

Chagas

* Launched in 2017

Targeting medication to atrial fibrillation patients

GDF-15 test predicts individual bleeding-risk

40

• 33 million people with atrial fibrillation globally,

at increased risk of stroke

• Today 50% of patients receive no stroke

prevention treatment due to perceived bleeding

risk

• GDF-15 informs on individual bleeding risks

and allows for more targeted treatment

decisions

Figure 3: Importance of variables considered for inclusion in the ABC-bleeding score (ARISTOTLE

derivation cohort; n=14,537) as assessed by Wald Regression. Adapted from Hijazi 2016.

1 The improved prognostic value of the ABC bleeding risk score is recognized in the 2016 European Society of Cardiology Guidelines

for the management of atrial fibrillation

FDA approval of first commercial Zika IVD test

Expanding our leading blood screening portfolio

41

cobas 6800/8800 Systems: 313 instruments placed in 33 markets***

MAY 2015

Zika outbreak confirmed in Brazil

DEC 2015

Locally-acquired Zika cases reported in Puerto Rico

FEB 2016

WHO declares international Public Health Emergency

MAR 2016

cobas® Zika test receives IND* status from FDA

APR 2016

Screening of Puerto Rico donations with cobas Zika IND*

JUL 2016

Transmission of Zika virus reported in Miami, FL

AUG 2016

FDA mandates US screening for Zika virus

APR 2017

BLA** submission to FDA for cobas®

Zika

OCT 2017

FDA approval of cobas® Zika test

*IND: Investigational New Device

**BLA: Biologics License Application

***Status YTD August 2017

Launch of NAVIFY tumor board

Entering digital information systems market

42

• Oncology care team workflow and decision support tool

• Aggregates patient data from multiple sources into a dashboard

• Improved team collaboration and efficiency, reduces errors

• Auditable decision tracking

• Patient data stored and accessed securely

Area Product Market

Instruments/

Devices

Central

Laboratory

cobas 8000 <e 801> – High throughput immunochemistry analyser

CCM High Speed – cobas connection module (CCM) for up to 6000 samples/hour

US

WW

Coagulation

Testing cobas t 511 / t 711 – Medium and high volume coagulation systems EU

Point of Care CoaguChek Vantus – Hand-held coagulation monitoring system for Patient Self-

Testing US

Diabetes Care Accu-Chek Instant bG System – Effortless, accurate and affordable bG system

for price sensitive markets EU

Tests/

Assays

HPV cobas HPV – Next generation HPV DNA test leveraging 68/8800 Automation to detect

14 hrHPV with simultaneous detection of genotypes 16 and 18

CINtec Histology – Diagnostic component of the Roche Cervical Cancer portfolio

EU

US

Virology cobas HIV 1&2 Qual – For use on the cobas 6800/8800 Systems; for diagnosis of acute

HIV 1 or 2 infection and for confirmation of HIV 1 or 2 infection EU

Sequencing AVENIO ctDNA panels - Liquid biopsy for circulating tumor DNA, 3 panels: targeted

panel (17 genes for cancer therapy selection), expanded panel (77 genes for cancer therapy selection), surveillance panel (197 genes)

EU/US

cobas Liat

cobas Liat C.diff – Qualitative IVD test, that utilizes real-time PCR, for the direct

detection of the tcdB gene of toxigenic C. difficile in unformed stool specimens

cobas Liat MRSA/SA – Qualitative IVD test, that utilizes real-time PCR, for the direct

detection of MRSA and Staphylococcus aureus DNA from nasal swabs

EU

EU

Women’s Health AMH – Immunoassay for the in vitro quantitative determination of anti-Mullerian hormone

(AMH) in human serum and plasma for the assessment of the ovarian reserve in women presenting to fertility clinics

US

Companion

Diagnostics

PD-L1 (SP142) for Bladder Cancer* – complementary diagnostic for Tecentriq

PD-L1 (SP142) for NSCLC* – complementary diagnostic for Tecentriq

EU

EU

Key launch list 2017

43 * = Achieve commercial readiness, dependent on Pharma label and approval

44

Finance Alan Hippe Chief Financial Officer

• Strong underlying Group sales growth, particularly in the US (+8%) and International

(+7%) regions

• +5% growth in both divisions

YTD Sept 2017: Highlights

45

Sales

• Negative impact from Other Europe currencies and JPY offset by Lat-Am currencies and

USD

Currency impact


Group sales YTD Sept 2017

Sales increase driven by US and Diagnostics Division

46 Absolute values and growth rates at Constant Exchange Rates (CER) 1 average Full Year 2016 to average YTD Sept 2017 Fx

+1,970

+1,361

-41

+1,929

-107+208 +54

+454

United States Europe Intl. Japan Diagnostics

Division

Group Fx Group

CHF

Pharma Division+5%

+10% -2% +4% +2% +5% +5% +5%

1

CER

sales

growth

YTD Sep

2017

vs.

YTD Sep

2016

Exchange rate impact on sales growth

Negative impact from Other Europe currencies and JPY offset by Lat-Am currencies and USD

CER=Constant Exchange Rates

CHF

sales

growth

YTD Sep

2017

vs.

YTD Sep

2016

+5.2% +5.1%

+0.2p +0.2p +0.1p 0.0p -0.1p -0.2p -0.3p

CER Lat-Am USD Other EUR As-Pac JPY Other

Europe

CHF

47

1.01 1.00 1.00 1.00 0.99 0.97 0.96 0.97 0.96 0.97 0.97 0.97

1.00 0.99

0.98

0.98 0.99

0.98 0.98

0.99

J F M A M J J A S O N D

1.07 1.07 1.07 1.07 1.09 1.09 1.10 1.14 1.15 1.14 1.14 1.14

1.07 1.08 1.09

1.11 1.10 1.10 1.09

1.09

J F M A M J J A S O N D

Low currency impact expected in 2017

Assuming the 30 September 2017 exchange

rates remain stable until end of 2017,

2017 impact is expected to be (%p):

CHF / USD

CHF / EUR

+1%

Average YTD 2016

1% 1% 0% 0%

-2% -2% 0% +1%

Assumed

average YTD

2017

Monthly avg fx rates 2017 Fx rates at 30 Sep 2017

48

Q1 HY Sep

YTD

FY

Sales 0 0 0

Core

operating

profit

0

Core EPS 0

2017 outlook raised at HY

49

Group sales growth1 Mid-single digit

Core EPS growth1 Broadly in line with sales growth

Dividend outlook Further increase dividend in Swiss francs

1 At Constant Exchange Rates (CER)

Pipeline summary

50

New to phase I New to phase II New to phase III New to registration

Changes to the development pipeline

Q3 2017 update

Removed from phase I Removed from phase II Removed from phase III Removed from registration

3 NMEs:

RG6160 NME – multiple myeloma

RG6147 NME – geographic

atrophy

RG7945 NME - glaucoma

1 AI:

RG3616 Erivedge + ruxolitinib –

myelofibrosis

1 NME transitioned from Ph II:

RG6206 anti-myostatin

adnectin – DMD

1 AI:

RG7446 Tecentriq + paclitaxel –

1L TNBC

1 AI following filing in US/EU:

RG1273 Perjeta + Herceptin –

HER2+ BC adj

1 AI following filing in US:

RG7204 Zelboraf – Erdheim-

Chester disease

3 NMEs:

RG3637 lebrikizumab – atopic

dermatitis (out-licensed)

RG7745 Flu A MAb – influenza A

RG7221 vanucizumab - mCRC

Status as of October 19, 2017

2 AIs:

RG1273 Perjeta + Herceptin -

1L HER2+ gastric cancer

RG7204 Zelboraf – BRAFm

melanoma adj

1 NME following EU approval:

RG7446 Tecentriq – 2L mUC

2 AIs following EU approval:

RG1569 Actemra – giant cell

arteritis

RG7446 Tecentriq – 2L+ NSCLC

1 CHU following Japan approval:

CHU Actemra – Takayasu arteritis

and giant cell arteritis

1 NME transitioned from Ph I:

RG6100 Tau MAb - Alzheimer’s

disease

1 AI:

RG7388 idasanutlin -

polycythemia vera

51

RG6026 CD20 TCB heme tumors

RG6047 SERD (2) ER+ (HER2-neg) mBC

RG6058 TIGIT ± Tecentriq solid tumors

RG6114 mPI3K alpha inh HR+ BC

RG6146 BET inh combos solid + heme tumors

RG6160 - multiple myeloma

RG6180 personalized cancer vaccine ± T oncology

RG6185 pan-RAF inh + Cotellic solid tumors

RG7155 emactuzumab + Tecentriq solid tumors

emactuzumab + selicrelumab solid tumors

RG7159 anti-CD20 combos heme tumors

RG7386 FAP-DR5 biMAb solid tumors

RG7421 Cotellic + Zelboraf + T melanoma

Cotellic + T 2L BRAF WT mM

RG7446

Tecentriq solid tumors

Tecentriq NMIBC

T-based Morpheus platform solid tumors

T + Avastin + Cotellic 2/3L CRC

T ± Avastin ± chemo HCC, GC, PaC

T ± Avastin ± chemo solid tumors

T + Cotellic solid tumors

T + ipi/IFN solid tumors

T + Tarceva/Alecensa NSCLC

T + anti-CD20 combos heme tumors

T ± lenalidomide ± daratumumab MM

T + K/HP HER2+ BC

T + HMA MDS

T + radium 223 mCRPC

T + guadecitabine AML

T + rucaparib ovarian ca

RG7461 FAP IL2v FP combos solid tumors

RG7601 Venclexta + Cotellic/idasanutlin AML

Venclexta ± azacitadine r/r MDS

RG7741 ChK1 inh solid tumors

RG7802 CEA TCB ± Tecentriq solid tumors

RG7813 CEA IL2v FP* + Tecentriq solid tumors

RG7828 CD20 TDB ± Tecentriq heme tumors

RG7876 selicrelumab (CD40) + T solid tumors

selicrelumab + vanucizumab solid tumors

RG7882 MUC16 ADC ovarian ca

RG7986 ADC r/r NHL

CHU Raf/MEK dual inh solid tumors

CHU glypican-3/CD3 biMAb solid tumors

RG6069 anti-fibrotic agent fibrosis

RG6107 C5 inh MAb PNH

RG7835 - autoimmune diseases

RG7880 IL-22Fc inflammatory diseases

RG7990 - asthma

RG6004 HBV LNA HBV

RG6080 nacubactam bact.infections

RG7854 TLR7 agonist (3) HBV

RG7861 anti-S. aureus TAC infectious diseases

RG7907 HBV Capsid (2) HBV

RG7992 FGFR1/KLB MAb metabolic diseases

RG6000 - ALS

RG6029 Nav1.7 inh (2) pain

RG7203 PDE10A inh schizophrenia

RG7906 - psychiatric disorders

IONIS ASO Huntington’s

RG6147 - geographic atrophy

RG7945 - glaucoma

CHU PTH1 recep. ago hypoparathyroidism

CHU - hyperphosphatemia

RG3502 Kadcyla + Tecentriq 2L HER2+ mBC

RG7388 Idasanutlin§ polycythemia vera

RG7421 Cotellic + Tecentriq ± taxane TNBC

RG7440 ipatasertib 1L TNBC

ipatasertib TNBC neoadj

RG7596 polatuzumab vedotin DLBCL

RG7601

Venclexta + Rituxan DLBCL

Venclexta + Rituxan r/r FL

Venclexta + azacitadine 1L MDS

RG7604 taselisib + letrozole (HER2-neg) BC neoadj

RG7686 codrituzumab liver cancer

RG3637 lebrikizumab ± Esbriet (NME) IPF

RG6125 Cadherin-11 MAb RA

RG6149 ST2 MAb asthma

RG7159 obinutuzumab lupus

RG7625 Cat-S antag autoimmune diseases

RG7845 BTK inh RA, lupus, CSU

CHU nemolizumab** pruritus in dialysis patients

PRO VAP-1 inh inflammatory disease

NOV TLR4 MAb autoimmune diseases

RG6152 CAP endonuclease inh influenza

CHU URAT1 inh gout

RG1662 basmisanil CIAS, post-stroke recovery

RG6083 olesoxime SMA

RG6100 Tau MAb§ Alzheimer’s

RG7314 V1a receptor antag autism

RG7916 SMN2 splicer(2) SMA

RG7935 α-synuclein MAb Parkinson's

RG3645 ranibizumab PDS wAMD

RG7716 VEGF-ANG2 biMAb wAMD, DME New Molecular Entity (NME) RG-No Roche/Genentech

Additional Indication (AI) CHU Chugai managed

Oncology IONIS IONIS managed

Immunology PRO Proximagen managed

Infectious Diseases NOV Novimmune managed

CardioMetabolism *INN: cergutuzumab amunaleukin

Neuroscience **out-licensed to Galderma and Maruho

Ophthalmology for atopic dermatitis

Other § FPI expected Q4 2017

T=Tecentriq; TCB=T cell bispecific;

TDB=T cell dependent bispecific

Phase I (40 NMEs + 23 AIs)


Phase II (19 NMEs + 11 AIs)

Roche Group development pipeline

52

RG3502 Kadcyla HER2+ BC adj

Kadcyla + Perjeta HER2+ BC adj

RG6013 emicizumab hemophilia A w/o FVIII inh

emicizumab Q4W hemophilia A

RG7388 idasanutlin + chemo AML

RG7440 ipatasertib + chemo 1L CRPC

RG7421 Cotellic + Zelboraf + T BRAFm melanoma

RG7446

Tecentriq NSCLC adj

Tecentriq MIBC adj

Tecentriq Dx+ 1L sq + non-sq SCLC

Tecentriq RCC adj

T + nab-paclitaxel 1L non-sq NSCLC

T + chemo+ Avastin 1L ovarian cancer

T + chemo + Avastin 1L non-sq NSCLC

T + chemo + pemetrexed 1L non-sq NSCLC

T + nab-paclitaxel 1L sq NSCLC

T + paclitaxel 1L TNBC

T + nab-paclitaxel 1 LTNBC

T + nab-paclitaxel TNBC neoadj

T + Avastin RCC

T + Cotellic 3L CRC

T ± chemo 1L mUC

T + chemo 1L extensive stage SCLC

T + enzalutamide CRPC

RG7601

Venclexta + Rituxan r/r CLL

Venclexta + Gazyva 1L CLL

Venclexta + bortezomib MM

Venclexta + HMA 1L AML

RG7604 taselisib + fulvestrant ER+(HER2-neg) mBC

RG105 MabThera pemphigus vulgaris

RG1569 Actemra systemic sclerosis

RG7413 etrolizumab ulcerative colitis

etrolizumab Crohn’s

RG1450 gantenerumab Alzheimer’s

RG6168 satralizumab (IL-6R MAb) NMO

RG6206 anti-myostatin adnectin DMD

RG7412 crenezumab Alzheimer’s

RG7417 lampalizumab geographic atrophy

RG3645 Lucentis 0,3mg PFS1 DME/DR

RG435 Avastin1 GBM

RG1273 Perjeta + Herceptin HER2+ BC adj

RG6013 emicizumab hemophilia A FVIII inh

RG7159 Gazyva2 1L FL

RG7204 Zelboraf1 Erdheim-Chester disease

RG7853 Alecensa 1L ALK+ NSCLC

RG1594 Ocrevus3 PPMS + RMS


1 US only

2

3 Approved in US

Approved in EU

Phase III (9 NMEs + 30 AIs) Registration (2 NMEs + 5 AIs)


New Molecular Entity (NME) RG-No Roche/Genentech


Oncology RG1569 Branded as RoActemra (EU)

Immunology RG7159 Branded as Gazyvaro (EU)

Infectious Diseases

CardioMetabolism

Neuroscience

Ophthalmology

Other T=Tecentriq

53

NME submissions and their additional indications

Projects currently in phase II and III

RG6013 emicizumab ✓

hemophilia A FVIII inh

pediatrics and adults

RG7604 taselisib+fulvestrant

PIK3CAmut ER+ (HER2-neg) mBC

RG6013

emicizumab hemophilia A FVIII non-inh

RG6013 emicizumab

hemophilia A, Q4W

RG7388 idasanutlin

polycythemia vera

RG7440 ipatasertib

1L CRPC

RG7440 ipatasertib

1L TNBC

RG7440 ipatasertib

TNBC neoadj

RG7596

polatuzumab vedotin DLBCL

RG7604 taselisib + letrozole

ER+ (HER2-neg) BC neoadj

RG1450 gantenerumab

Alzheimer‘s

RG1662

basmisanil CIAS, post-stroke

recovery

RG6083 olesoxime

SMA

RG6100 Tau MAb

Alzheimer’s

RG6206

anti-myostatin adnectin

DMD

RG7314 V1 receptor antag

autism

RG7412 crenezumab Alzheimer’s

RG7916 SMN2 splicer(2)

SMA

RG7935 α-synuclein MAb

Parkinson’s

RG7716 VEGF/ANG2 biMAb

wAMD/DME

RG6152

CAP endonuclease inh

influenza

RG3637

lebrikizumab ± Esbriet

IPF

RG6125 Cadherin-11 MAb

RA

RG6149 ST2 MAb Asthma

RG7413 etrolizumab

ulcerative colitis

RG7413 etrolizumab

Crohn’s

RG7625 Cat S antag

autoimmune diseases

RG7845 BTK inh

autoimmune diseases

2018 2017 2020 and beyond 2019

RG6168 satralizumab

IL-6R MAb, SA237 neuromyelitis optica

RG7388 idasanutlin

AML

New Molecular Entity (NME) CardioMetabolism

Additional Indication (AI) Neuroscience

Oncology Ophthalmology

Immunology Other

Infectious Diseases

✓ Indicates a submission which has occurred with regulatory action pending

Unless stated otherwise submissions are planned to occur in US and EU


54

AI submissions for existing products

Projects currently in phase II and III

✓ Indicates submission to health authorities has occurred

Unless stated otherwise submissions are planned to occur in US and EU

2018 2017 2020 and beyond 2019

RG3645

Lucentis 0.3mg PFS (US)

DME/DR

RG435 Avastin (US) ✓

GBM

RG1273 Perjeta + Herceptin ✓

HER2+ BC adj.

RG7159 Gazyva (US) ✓

1L FL

RG7204 Zelboraf (US) ✓

Erdheim-Chester disease

RG7601 Venclexta + Rituxan

r/r CLL

RG7853 Alecensa ✓

1L ALK+ NSCLC

RG105 MabThera

pemphigus vulgaris

RG1569 Actemra

systemic sclerosis

RG7446

Tecentriq + chemo + Avastin

1L non-sq NSCLC

RG7446

Tecentriq + nab-paclitaxel

1L sq NSCLC

RG7446


1L non-sq NSCLC

RG7446

Tecentriq + chemo + pemetrexed

1L non-sq NSCLC

RG7446 Tecentriq + chemo

1L extens. stage SCLC

RG7446 Tecentriq + Avastin

RCC

RG7446


TNBC

RG3502 Kadcyla + Tecentriq

2L Her2+ mBC

RG3502 Kadcyla + Perjeta

HER2+ BC adj.

RG3502 Kadcyla

HER2+ BC adj.


r/r FL


DLBCL

RG7601 Venclexta + HMA

1L AML

RG7601 Venclexta + HMA

1L MDS

RG7421

Cotellic + Tecentriq ± taxane

TNBC

RG3645 ranibizumab PDS

wAMD

RG7159 obinutuzumab

lupus nephritis

RG7446 Tecentriq ± chemo

1L mUC

RG7446 Tecentriq NSCLC adj

RG7446 Tecentriq MIBC adj

RG7446

Tecentriq + enzalutamide

CRPC

RG7446 Tecentriq RCC adj

RG7446

Tecentriq + chemo + Avastin

1L ovarian cancer




Immunology Other

Infectious Diseases

RG7446 Tecentriq + Cotellic

3L CRC

RG7421

Cotellic + Tecentriq + Zelboraf

BRAFmut melanoma

RG7446

Tecentriq 1L non-sq + sq NSCLC (Dx+)

RG7446

Tecentriq+ nab-paclitaxel

TNBC neoadj

RG7446 Tecentriq + paclitaxel

1L TNBC

RG7601 Venclexta + Gazyva

1L CLL

RG7601

Venclexta + bortezomib

MM


55

EU Japan-Chugai US

RG105

Rituxan Hycela™ (SC)

NHL/CLL

June 2017

RG7446

Tecentriq 1L bladder cancer, cis-ineligible

April 2017

RG1569

Actemra giant cell arteritis

May 2017

RG1569

Actemra CRS

August 2017

RG1594

Ocrevus

PPMS & RMS

March 2017

RG3645

Lucentis mCNV

January 2017

RG3645

Lucentis diabetic retinopathy w/o DME

April 2017

RG435

Avastin GBM

Filed February 2017

RG1273

Perjeta + Herceptin HER2+ BC adj Filed July 2017

RG6013

emicizumab hemophilia A FVIII inh (pediatrics and adults)

Filed June 2017

RG7159

Gazyva

follicular lymphoma 1L

Filed June 2017

RG7204

Zelboraf

Erdheim-Chester disease

Filed June 2017

RG7853

Alecensa 1L ALK+ NSCLC Filed May 2017

RG1273

Perjeta + Herceptin HER2+ BC adj

Filed August 2017

RG6013


Filed June 2017

RG7853

Alecensa

1L ALK+ NSCLC

Filed March 2017

RG1594

Ocrevus

PPMS & RMS

Filed April 2016

Approved

Pending Approval

RG6013


Filed July 2017

RG7446

Tecentriq

2L+ NSCLC

Filed February 2017

RG435

Avastin

chemo backbone extension

rel. OC Pt-sensitive

June 2017

RG7159

Gazyva

1L follicular lymphoma

September 2017

RG7446

Tecentriq

mUC 2L

September 2017

RG7446

Tecentriq

2L+ NSCLC

September 2017

RG7853

Alecensa

2L ALK+ NSCLC

February 2017

RG1569

Actemra

giant cell arteritis

September 2017




Immunology Other

Infectious Diseases

CHU

Actemra

Takayasu arteritis and

giant cell arteritis

August 2017

56


Major granted and pending approvals 2017


Combinations


RG6146 BET inh combos solid + heme tumors


RG6185 pan-RAF inh + Cotellic solid tumors


emactuzumab + selicrelumab solid tumors

RG7159 anti-CD20 combos heme tumors


Cotellic + T BRAF WT mM2L

RG7446

T-based Morpheus platform solid tumors

T + Avastin + Cotellic 2/3L CRC






T + anti-CD20 combos heme tumors


T + K/HP HER2+ BC

T + HMA MDS




RG7461 FAP IL2v FP combos solid tumors

RG7601 Venclexta + Cotellic/idasanutlin AML

Venclexta ± azacitidine r/r MDS



RG7601

Venclexta + Rituxan DLBCL

Venclexta + Rituxan r/r FL

Venclexta + azacitidine 1L MDS

RG7604 taselisib + letrozole (HER2-) BC neoadj

RG3637 lebrikizumab ± Esbriet (NME) IPF

Phase II (1 NME + 6 AIs)

RG3502 Kadcyla + Perjeta HER2+ BC adj

RG7388 idasanutlin + chemo AML

RG7440 ipatasertib + chemo 1L CRPC


RG7446


T + chemo + Avastin 1L ovarian cancer




T + nab-paclitaxel 1L TNBC


T + Cotellic 3L CRC

T + Avastin RCC

T ± chemo 1L mUC

T + chemo 1L extens. stage SCLC



RG7601

Venclexta + Rituxan r/r CLL

Venclexta + Gazyva 1L CLL

Venclexta + bortezomib MM

Venclexta + HMA 1L AML

RG7604 taselisib + fulvestrant ER+ (HER2-neg) mBC

Phase III (3 NMEs + 19 AIs)



Oncology *INN: cergutuzumab amunaleukin

Immunology T=Tecentriq; TCB=T cell bispecific



RG1273 Perjeta + Herceptin HER2+ BC adj

Registration (1 AI)

57




RG7828 CD20 TDB ± Tecentriq heme tumors



Cancer immunotherapy pipeline overview

RG6026 CD20 TCB hematopoietic tumors


RG6160 - multiple myeloma



emactuzumab + selicrezumab solid tumors


Cotellic + T BRAF WT mM2L

RG7446

Tecentriq solid tumors

Tecentriq NMIBC

T-based Morpheus platform pancreatic ca

T + Cotellic ± Avastin 2/3L CRC






T + anti-CD20 multiple combos lymphoma


T + K/HP HER2+ BC

T + HMA MDS




RG7461 FAP IL2v FP + Tecentriq ± Avastin RCC



RG7828 CD20 TDB ± Tecentriq solid tumors





IMDZ** Tecentriq + NY-ESO-1 soft tissue sarcoma

SNDX** Tecentriq + entinostat TNBC


RG7446

Tecentriq NSCLC adj

Tecentriq MIBC adj

Tecentriq Dx+ 1L sq + non-sq SCLC

Tecentriq RCC adj


T + chemo + Avastin 1L ovarian cancer




T + nab-paclitaxel 1L TNBC


T + Avastin RCC

T + Cotellic 3L CRC

T ± chemo 1L mUC

T + chemo 1L extensive stage SCLC



** External collaborations: HALO – Halozyme PEGPH20; INCY- Incyte IDO inh; CLDX - Celldex CD27 MAb; CRVS – Corvus ADORA2A antag; KITE – Kite KTE-C19; AMGN – Amgen oncolytic virus; JNJ – Janssen CD38 MAb; CLVS – Clovis PARP inh; EPZM – Epizyme EZH2 inh; BLRX - BioLine Rx CXCR4 antag; IMDZ – Immune Design CMB305; SNDX – Syndax HDAC inh


Additional Indication (AI) *INN: cergutuzumab amunaleukin

Oncology T=Tecentriq; TCB=T cell bispecific


RG7446 T-based Morpheus pancreatic cancer

T-based Morpheus gastric cancer

AMGN** Tecentriq + talimogene laherp TNBC, CRC

BLRX** Tecentriq + BL-8040 AML, solid tumors

CLDX** Tecentriq + varlilumab solid tumors

CLVS** Tecentriq + rucaparib ovarian ca

CRVS** Tecentriq + CPI-444 solid tumors

EPZM** Tecentriq + tazemetostat r/r DLBCL

HALO** Tecentriq + PEGPH20 CCC, GBC

INCY** Tecentriq + epacadostat solid tumors

JNJ** Tecentriq ± daratumumab solid tumors

KITE** Tecentriq + KTE-C19 r/r DLBCL


Phase III (18 AIs)

Phase II (4 AIs)

MORPHEUS Platform - Phase Ib/II (2 AIs)


58

Doing now what patients need next

Documents

Roche YTD September 2017 salesbf6a0b14-e682-4af8-b4e1-7cc59c2e23… · 3 This presentation contains certain forward-looking statements. These forward-looking statements may be identified